HC Wainwright Has Bearish Estimate for MLYS FY2026 Earnings

Key Points

• HC Wainwright lowered its FY2026 EPS estimate for Mineralys Therapeutics to a loss of $4.56 per share from a loss of $4.40, while retaining a Buy rating and a $56 price target.
• Mineralys reported a quarterly loss of $0.64 per share, missing analyst expectations of a $0.55 loss by $0.09.
• Analyst views are mixed: the stock has a consensus Hold rating and a $45.50 consensus price target, while shares opened at $15.33 against a 12-month range of $14.91 to $47.65.

Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) - HC Wainwright reduced their FY2026 earnings per share estimates for Mineralys Therapeutics in a research note issued on Thursday, November 5th. HC Wainwright analyst M. Caufield now expects that the company will post earnings of ($4.56) per share for the year, down from their prior forecast of ($4.40). HC Wainwright currently has a "Buy" rating and a $56.00 price target on the stock. The consensus estimate for Mineralys Therapeutics' current full-year earnings is ($4.60) per share. HC Wainwright also issued estimates for Mineralys Therapeutics' Q4 2026 earnings at ($0.64) EPS and FY2027 earnings at ($2.35) EPS.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.09).

A number of other research firms have also weighed in on MLYS. UBS Group assumed coverage on shares of Mineralys Therapeutics in a research note on Sunday, October 11th. They issued a "neutral" rating and a $29.00 price objective on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Mineralys Therapeutics in a research report on Thursday, October 15th. Wall Street Zen lowered shares of Mineralys Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday, August 15th. Finally, Zacks Research raised Mineralys Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Friday, September 11th. Five research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $45.50.

Mineralys Therapeutics Stock Performance

Shares of NASDAQ MLYS opened at $15.33 on Monday. The company has a current ratio of 11.83, a quick ratio of 11.83 and a debt-to-equity ratio of 0.15. Mineralys Therapeutics has a 12 month low of $14.91 and a 12 month high of $47.65. The company has a 50 day simple moving average of $23.78 and a two-hundred day simple moving average of $26.61. The stock has a market cap of $1.36 billion, a price-to-earnings ratio of -3.52 and a beta of 0.83.

Insider Activity

In other Mineralys Therapeutics news, insider Eric Warren sold 7,438 shares of the company's stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $28.12, for a total value of $209,156.56. Following the completion of the transaction, the insider owned 38,400 shares in the company, valued at approximately $1,079,808. This represents a 16.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Brian Slingsby sold 104,320 shares of the stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $28.81, for a total transaction of $3,005,459.20. Following the sale, the director directly owned 7,805,718 shares in the company, valued at approximately $224,882,735.58. The trade was a 1.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 197,195 shares of company stock worth $5,403,069 in the last ninety days. Corporate insiders own 18.94% of the company's stock.

Hedge Funds Weigh In On Mineralys Therapeutics

A number of large investors have recently bought and sold shares of MLYS. BlackRock Inc. purchased a new stake in shares of Mineralys Therapeutics during the second quarter worth about $158,832,000. Orbimed Advisors LLC lifted its stake in Mineralys Therapeutics by 109.4% in the 1st quarter. Orbimed Advisors LLC now owns 2,052,900 shares of the company's stock valued at $55,613,000 after buying an additional 1,072,500 shares in the last quarter. Bank of America Corp DE acquired a new stake in Mineralys Therapeutics in the 2nd quarter worth about $40,620,000. Jennison Associates LLC boosted its holdings in Mineralys Therapeutics by 0.6% in the 1st quarter. Jennison Associates LLC now owns 1,266,174 shares of the company's stock worth $34,301,000 after buying an additional 7,521 shares during the last quarter. Finally, Aberdeen Group plc boosted its holdings in Mineralys Therapeutics by 29.8% in the 3rd quarter. Aberdeen Group plc now owns 894,403 shares of the company's stock worth $22,476,000 after buying an additional 205,168 shares during the last quarter. Institutional investors and hedge funds own 84.46% of the company's stock.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and kidney diseases associated with excess aldosterone activity. The company's research centers on selectively targeting aldosterone production, a mechanism involved in blood-pressure regulation and organ damage.

Mineralys' lead product candidate is lorundrostat, an oral, selective aldosterone synthase inhibitor being evaluated as a potential treatment for uncontrolled and resistant hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.